Prospective, open label clinical study for stereotactic radiotherapy combined with erlotinib in the treatment of brain metastases from lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027546

Enrollment

Unknown

Registered

2019-11-17

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer brain metastases

Interventions

Experimental group:stereotactic radiotherapy combined with erlotinib

Control group:stereotactic radiotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Lung cancer patients who have experienced at least 2 kinds of systemic chemotherapy after brain metastases; 2. The number of brain metastases =80 points.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to pharmaceutical ingredients; 2. Those who have central lung squamous cell carcinoma or who have a risk of massive hemoptysis; 3. Those who have severe liver and kidney dysfunction; 4. Women who are pregnant and lactating; 5. Brainstem metastasis.

Design outcomes

Primary

Measure	Time frame
OS;	—

Secondary

Measure	Time frame
PFS;ORR;DCR;	—

Countries

China

Contacts

Public ContactYingqiu Song

1018501023@qq.com+86 18900917411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026